Related Experiment Videos
[HER2 expression and its prognostic implication in lymph node negative breast carcinoma: a Meta-analysis].
Hua Guo1, Bing Wei, Hong-ying Zhang
1Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China.
Summary
HER2 overexpression occurs in 23.14% of lymph node-negative breast cancer patients, indicating a poor prognosis. Adjuvant therapy post-surgery is recommended for improved survival outcomes in these cases.
Area of Science:
- Oncology
- Genetics
- Pathology
Context:
- Human epidermal growth factor receptor 2 (HER2) is a key oncogene in breast cancer.
- HER2 overexpression is a known driver of aggressive tumor behavior.
- Accurate prognostic markers are crucial for guiding treatment decisions in early-stage breast cancer.
Purpose:
- To determine the prevalence of HER2 overexpression in lymph node-negative breast cancer.
- To evaluate the prognostic significance of HER2 overexpression on disease-free survival (DFS) and overall survival (OS).
- To assess the predictive value of HER2 status in relation to adjuvant therapy.
Summary:
- A meta-analysis of 56 studies found HER2 overexpression in 23.14% of lymph node-negative breast cancers (IHC: 23.13%, FISH: 20.90%).
- Seven studies demonstrated that HER2 overexpression (IHC and FISH) independently predicts poor DFS and OS (P < 0.05).
- HER2 status effectively predicted outcomes without adjuvant therapy and OS with adjuvant therapy.
Impact:
- This study confirms HER2 overexpression as a significant negative prognostic factor in early breast cancer.
- Findings support the use of HER2 testing for risk stratification and treatment planning.
- Results underscore the importance of considering adjuvant therapy in HER2-positive, lymph node-negative patients.